Research
Hormonal
Exposure to Endocrine-Disrupting Chemicals (EDCs) such as Bisphenol A (BPA) and Diethylstilbestrol (DES) during fetal development can cause transgenerational epigenetic changes leading to increased risks of cancer, obesity, and reproductive disorders in offspring and subsequent generations.
Minimize exposure to endocrine disruptors like BPA (found in some plastics) and DES-like compounds. Use glass or stainless steel containers for food storage, avoid heating food in plastic, and choose fresh foods over canned when possible to reduce intake of these chemicals, especially during pregnancy.
GoodSupportsHIGH confidence
There is increasing evidence to suggest that EDC exposure during early life, in particular during fetal development, contributes to a variety of diseases, including cancers, which manifest later in life or even in the next generation. This suggests epigenetic inheritance of EDC-related events.
Why this rating
Cites multiple human and animal studies showing clear associations between EDC exposure and disease.
Source
The Impact of Nutrition and Environmental Epigenetics on Human Health and Disease
Céline Tiffon · International Journal of Molecular Sciences · 2018
DOI 10.3390/ijms19113425
narrative_reviewCited 486×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Adherence to a Mediterranean diet, particularly when supplemented with extra-virgin olive oil or nuts, reduces the incidence of major cardiovascular events and breast cancer risk compared to a reduced-fat diet.Good
- Maternal intake of methyl-donating nutrients (folate, vitamin B12) during pregnancy can counteract the negative epigenetic effects of environmental toxins like Bisphenol A (BPA), preventing adverse offspring phenotypes such as obesity and cancer susceptibility.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →